Add BrightSurf on Google Email

Sbarro Health Research Organization


Promising results shown for kidney cancer drug

A new study published in Journal of Clinical Oncology found that pazopanib slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54%. The drug targets multiple pathways within cancer cells, inhibiting blood vessel development. Common side effects include diarrhea, hypertension, and weight loss.

SourceSbarro Health Research Organization·JournalJournal of Clinical Oncology·DateFeb 4, 2010